AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
22 déc. 2023 07h00 HE
|
AlloVir Inc.
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety...
AlloVir Reports Third Quarter 2020 Financial Results
10 nov. 2020 07h00 HE
|
AlloVir Inc.
- Completed initial public offering raising $317.7M in gross proceeds - Viralym-M (multi-virus-specific T cell therapy) registrational study in lead indication in virus-associated hemorrhagic...
AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting
04 nov. 2020 13h33 HE
|
AlloVir Inc.
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that...
Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
21 oct. 2020 07h30 HE
|
AlloVir Inc.
CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that health outcomes analyses to be presented at IDWeek™ 2020...
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
17 sept. 2020 09h49 HE
|
AlloVir Inc.
- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients - Proof-of-concept clinical trial with ALVR109 to...
AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer
08 sept. 2020 16h15 HE
|
AlloVir Inc.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced the appointment of Ercem Atillasoy, M.D., as the company’s Chief...
AlloVir Reports Second Quarter 2020 Financial Results
02 sept. 2020 07h30 HE
|
AlloVir Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020. ...
AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
25 août 2020 07h30 HE
|
AlloVir Inc.
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th...
AlloVir Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
03 août 2020 16h30 HE
|
AlloVir Inc.
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offering of...
AlloVir Announces Pricing of Upsized Initial Public Offering
30 juil. 2020 07h32 HE
|
AlloVir Inc.
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offering of...